mTOR Inhibition by Everolimus Does Not Impair Closure of Punch Biopsy Wounds in Renal Transplant Patients

BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are approved to prevent allograft rejection and control malignancy. Unfortunately, they are associated with adverse effects, such as wound healing complications that detract from more extensive use. There is a lack of prospective wound heal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transplant Direct
Main Authors: Dutt, Shelley B., Gonzales, Josephine, Boyett, Megan, Costanzo, Anne, Han, Peggy P., Steinberg, Steven, McKay, Dianne B., Jameson, Julie M.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2017
Assuntos:
Kidney Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5381740/
https://ncbi.nlm.nih.gov/pubmed/28405603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TXD.0000000000000663
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados